



PC25319A

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: DANIEL FRED ORTWINE  
SERIAL NO.: 10/634,718  
FILED: AUGUST 5, 2003  
FOR: CHROMONE DERIVATIVES AS MATRIX  
METALLOPROTEINASE INHIBITORS

EXAMINER: KAH SAY HABTE  
ART UNIT: 1624  
CONFIRMATION NO: 8926

AMENDMENTS AND REPLY TO OFFICE ACTION

*For  
purpose  
only*

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Dear Sir:

This paper is in response to the Office Action date mailed 09/27/2004 by the U.S. Patent and Trademark Office (hereinafter the "Office") in the above-referenced application. Applicant respectfully requests the following amendments to be made to the application.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 13 of this paper.

12/15/2004 DWILLIA4 00000003 230455 10634718  
01 FC:1806 180.00 DA

Page 1 of 15

FEE VALUE		ACCOUNTABILITY	
DEPOSIT ACCOUNT NO.			
23	0455		
Fee	Value	Code	Furnished
1806	180	06	06

which incorporates the definition of "(C<sub>1</sub>-C<sub>8</sub> alkylene)" provided on line 27 on page 56 though line 2 on page 57; definition of "naphthyl-(C<sub>1</sub>-C<sub>8</sub> alkylene)" is found at lines 10-13 on page 59, which incorporates both the definition of "(C<sub>1</sub>-C<sub>8</sub> alkylene)" provided at line 27 on page 56 though line 2 on page 57, and the definition of "naphthyl" provided on line 9 on page 59; and, finally, definition of "cycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylene)" is seen on page 57 at lines 10-13 (for "C<sub>3</sub>-C<sub>6</sub> cycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylene)") and lines 19-21 (for "C<sub>5</sub> or C<sub>6</sub> cycloalkyl-(C<sub>1</sub>-C<sub>8</sub> alkylene")", both incorporating the definition of "C<sub>1</sub>-C<sub>8</sub> alkylene" provided at line 27 on page 56 though line 2 on page 57.

For the above reasons, Applicant believes that the rejection to claim 1 as amended, as well as its dependent claims 2, 3, 5-10, and 13-17, should be withdrawn. In addition, new claims 18 and 19 ultimately depend from claim 1. For the same reasons as provided for claim 1 above, Applicant believes that claims 18 and 19 are clear and definite.

The Examiner also indicates that in claim 10 (page 135) the nomenclature of the two species "benzo[1,3]oxazin-4-one" is incorrect. Applicant, who agrees with the Examiner, wishes to point out that this is a typographical error. Claim 10 has been amended to recite the correct nomenclature "benzo[1,3]oxazin-4-one" as suggested by Examiner.

#### C. Concluding Remarks

In view of the above amendments and remarks, Applicant respectfully requests reconsideration of the application, withdrawal of the rejections, and timely issuance of Notice of Allowance.

Respectfully submitted,

Dated: Nov. 17, 2004



Austin W. Zhang  
Registration No. 48,081  
Warner-Lambert Company LLC  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Telephone: (734) 622-5035  
Facsimile: (734) 622-1553